Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV

Duration of protection from SARS-CoV-2 infection in people living with HIV (PWH) following vaccination is unclear. In a substudy of the phase II/III the COV002 trial (NCT04400838), 54 HIV+ male participants on antiretroviral therapy (undetectable viral loads, CD4+ T cells > 350 cells/μL) rece...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Ane Ogbe [verfasserIn] Matthew Pace [verfasserIn] Mustapha Bittaye [verfasserIn] Timothy Tipoe [verfasserIn] Sandra Adele [verfasserIn] Jasmini Alagaratnam [verfasserIn] Parvinder K. Aley [verfasserIn] M. Azim Ansari [verfasserIn] Anna Bara [verfasserIn] Samantha Broadhead [verfasserIn] Anthony Brown [verfasserIn] Helen Brown [verfasserIn] Federica Cappuccini [verfasserIn] Paola Cinardo [verfasserIn] Wanwisa Dejnirattisai [verfasserIn] Katie J. Ewer [verfasserIn] Henry Fok [verfasserIn] Pedro M. Folegatti [verfasserIn] Jamie Fowler [verfasserIn] Leila Godfrey [verfasserIn] Anna L. Goodman [verfasserIn] Bethany Jackson [verfasserIn] Daniel Jenkin [verfasserIn] Mathew Jones [verfasserIn] Stephanie Longet [verfasserIn] Rebecca A. Makinson [verfasserIn] Natalie G. Marchevsky [verfasserIn] Moncy Mathew [verfasserIn] Andrea Mazzella [verfasserIn] Yama F. Mujadidi [verfasserIn] Lucia Parolini [verfasserIn] Claire Petersen [verfasserIn] Emma Plested [verfasserIn] Katrina M. Pollock [verfasserIn] Thurkka Rajeswaran [verfasserIn] Maheshi N. Ramasamy [verfasserIn] Sarah Rhead [verfasserIn] Hannah Robinson [verfasserIn] Nicola Robinson [verfasserIn] Helen Sanders [verfasserIn] Sonia Serrano [verfasserIn] Tom Tipton [verfasserIn] Anele Waters [verfasserIn] Panagiota Zacharopoulou [verfasserIn] Eleanor Barnes [verfasserIn] Susanna Dunachie [verfasserIn] Philip Goulder [verfasserIn] Paul Klenerman [verfasserIn] Gavin R. Screaton [verfasserIn] Alan Winston [verfasserIn] Adrian V.S. Hill [verfasserIn] Sarah C. Gilbert [verfasserIn] Miles Carroll [verfasserIn] Andrew J. Pollard [verfasserIn] Sarah Fidler [verfasserIn] Julie Fox [verfasserIn] Teresa Lambe [verfasserIn] John Frater [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2022

Schlagwörter:	AIDS/HIV COVID-19

Übergeordnetes Werk:	In: JCI Insight - American Society for Clinical investigation, 2020, 7(2022), 7
Übergeordnetes Werk:	volume:7 ; year:2022 ; number:7

Links:	Link aufrufen Link aufrufen Journal toc

Katalog-ID:	DOAJ043577830

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ043577830
003	DE-627
005	20230308072853.0
007	cr uuu---uuuuu
008	230227s2022 xx \|\|\|\|\|o 00\| \|\|eng c
035			\|a (DE-627)DOAJ043577830
035			\|a (DE-599)DOAJ446dfee8ec4944f5951afc9fd4bc0066
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
100	0		\|a Ane Ogbe \|e verfasserin \|4 aut
245	1	0	\|a Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV
264		1	\|c 2022
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Duration of protection from SARS-CoV-2 infection in people living with HIV (PWH) following vaccination is unclear. In a substudy of the phase II/III the COV002 trial (NCT04400838), 54 HIV+ male participants on antiretroviral therapy (undetectable viral loads, CD4+ T cells > 350 cells/μL) received 2 doses of ChAdOx1 nCoV-19 (AZD1222) 4–6 weeks apart and were followed for 6 months. Responses to vaccination were determined by serology (IgG ELISA and Meso Scale Discovery [MSD]), neutralization, ACE-2 inhibition, IFN-γ ELISpot, activation-induced marker (AIM) assay and T cell proliferation. We show that, 6 months after vaccination, the majority of measurable immune responses were greater than prevaccination baseline but with evidence of a decline in both humoral and cell-mediated immunity. There was, however, no significant difference compared with a cohort of HIV-uninfected individuals vaccinated with the same regimen. Responses to the variants of concern were detectable, although they were lower than WT. Preexisting cross-reactive T cell responses to SARS-CoV-2 spike were associated with greater postvaccine immunity and correlated with prior exposure to beta coronaviruses. These data support the ongoing policy to vaccinate PWH against SARS-CoV-2, and they underpin the need for long-term monitoring of responses after vaccination.
650		4	\|a AIDS/HIV
650		4	\|a COVID-19
653		0	\|a Medicine
653		0	\|a R
700	0		\|a Matthew Pace \|e verfasserin \|4 aut
700	0		\|a Mustapha Bittaye \|e verfasserin \|4 aut
700	0		\|a Timothy Tipoe \|e verfasserin \|4 aut
700	0		\|a Sandra Adele \|e verfasserin \|4 aut
700	0		\|a Jasmini Alagaratnam \|e verfasserin \|4 aut
700	0		\|a Parvinder K. Aley \|e verfasserin \|4 aut
700	0		\|a M. Azim Ansari \|e verfasserin \|4 aut
700	0		\|a Anna Bara \|e verfasserin \|4 aut
700	0		\|a Samantha Broadhead \|e verfasserin \|4 aut
700	0		\|a Anthony Brown \|e verfasserin \|4 aut
700	0		\|a Helen Brown \|e verfasserin \|4 aut
700	0		\|a Federica Cappuccini \|e verfasserin \|4 aut
700	0		\|a Paola Cinardo \|e verfasserin \|4 aut
700	0		\|a Wanwisa Dejnirattisai \|e verfasserin \|4 aut
700	0		\|a Katie J. Ewer \|e verfasserin \|4 aut
700	0		\|a Henry Fok \|e verfasserin \|4 aut
700	0		\|a Pedro M. Folegatti \|e verfasserin \|4 aut
700	0		\|a Jamie Fowler \|e verfasserin \|4 aut
700	0		\|a Leila Godfrey \|e verfasserin \|4 aut
700	0		\|a Anna L. Goodman \|e verfasserin \|4 aut
700	0		\|a Bethany Jackson \|e verfasserin \|4 aut
700	0		\|a Daniel Jenkin \|e verfasserin \|4 aut
700	0		\|a Mathew Jones \|e verfasserin \|4 aut
700	0		\|a Stephanie Longet \|e verfasserin \|4 aut
700	0		\|a Rebecca A. Makinson \|e verfasserin \|4 aut
700	0		\|a Natalie G. Marchevsky \|e verfasserin \|4 aut
700	0		\|a Moncy Mathew \|e verfasserin \|4 aut
700	0		\|a Andrea Mazzella \|e verfasserin \|4 aut
700	0		\|a Yama F. Mujadidi \|e verfasserin \|4 aut
700	0		\|a Lucia Parolini \|e verfasserin \|4 aut
700	0		\|a Claire Petersen \|e verfasserin \|4 aut
700	0		\|a Emma Plested \|e verfasserin \|4 aut
700	0		\|a Katrina M. Pollock \|e verfasserin \|4 aut
700	0		\|a Thurkka Rajeswaran \|e verfasserin \|4 aut
700	0		\|a Maheshi N. Ramasamy \|e verfasserin \|4 aut
700	0		\|a Sarah Rhead \|e verfasserin \|4 aut
700	0		\|a Hannah Robinson \|e verfasserin \|4 aut
700	0		\|a Nicola Robinson \|e verfasserin \|4 aut
700	0		\|a Helen Sanders \|e verfasserin \|4 aut
700	0		\|a Sonia Serrano \|e verfasserin \|4 aut
700	0		\|a Tom Tipton \|e verfasserin \|4 aut
700	0		\|a Anele Waters \|e verfasserin \|4 aut
700	0		\|a Panagiota Zacharopoulou \|e verfasserin \|4 aut
700	0		\|a Eleanor Barnes \|e verfasserin \|4 aut
700	0		\|a Susanna Dunachie \|e verfasserin \|4 aut
700	0		\|a Philip Goulder \|e verfasserin \|4 aut
700	0		\|a Paul Klenerman \|e verfasserin \|4 aut
700	0		\|a Gavin R. Screaton \|e verfasserin \|4 aut
700	0		\|a Alan Winston \|e verfasserin \|4 aut
700	0		\|a Adrian V.S. Hill \|e verfasserin \|4 aut
700	0		\|a Sarah C. Gilbert \|e verfasserin \|4 aut
700	0		\|a Miles Carroll \|e verfasserin \|4 aut
700	0		\|a Andrew J. Pollard \|e verfasserin \|4 aut
700	0		\|a Sarah Fidler \|e verfasserin \|4 aut
700	0		\|a Julie Fox \|e verfasserin \|4 aut
700	0		\|a Teresa Lambe \|e verfasserin \|4 aut
700	0		\|a John Frater \|e verfasserin \|4 aut
773	0	8	\|i In \|t JCI Insight \|d American Society for Clinical investigation, 2020 \|g 7(2022), 7 \|w (DE-627)872610594 \|w (DE-600)2874757-4 \|x 23793708 \|7 nnns
773	1	8	\|g volume:7 \|g year:2022 \|g number:7
856	4	0	\|u https://doaj.org/article/446dfee8ec4944f5951afc9fd4bc0066 \|z kostenfrei
856	4	0	\|u https://doi.org/10.1172/jci.insight.157031 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2379-3708 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 7 \|j 2022 \|e 7

Indexfelder

author_variant	a o ao m p mp m b mb t t tt s a sa j a ja p k a pka m a a maa a b ab s b sb a b ab h b hb f c fc p c pc w d wd k j e kje h f hf p m f pmf j f jf l g lg a l g alg b j bj d j dj m j mj s l sl r a m ram n g m ngm m m mm a m am y f m yfm l p lp c p cp e p ep k m p kmp t r tr m n r mnr s r sr h r hr n r nr h s hs s s ss t t tt a w aw p z pz e b eb s d sd p g pg p k pk g r s grs a w aw a v h avh s c g scg m c mc a j p ajp s f sf j f jf t l tl j f jf
matchkey_str	article:23793708:2022----::uaiiyfhdxno1vciainnep
hierarchy_sort_str	2022
publishDate	2022
allfields	(DE-627)DOAJ043577830 (DE-599)DOAJ446dfee8ec4944f5951afc9fd4bc0066 DE-627 ger DE-627 rakwb eng Ane Ogbe verfasserin aut Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Duration of protection from SARS-CoV-2 infection in people living with HIV (PWH) following vaccination is unclear. In a substudy of the phase II/III the COV002 trial (NCT04400838), 54 HIV+ male participants on antiretroviral therapy (undetectable viral loads, CD4+ T cells > 350 cells/μL) received 2 doses of ChAdOx1 nCoV-19 (AZD1222) 4–6 weeks apart and were followed for 6 months. Responses to vaccination were determined by serology (IgG ELISA and Meso Scale Discovery [MSD]), neutralization, ACE-2 inhibition, IFN-γ ELISpot, activation-induced marker (AIM) assay and T cell proliferation. We show that, 6 months after vaccination, the majority of measurable immune responses were greater than prevaccination baseline but with evidence of a decline in both humoral and cell-mediated immunity. There was, however, no significant difference compared with a cohort of HIV-uninfected individuals vaccinated with the same regimen. Responses to the variants of concern were detectable, although they were lower than WT. Preexisting cross-reactive T cell responses to SARS-CoV-2 spike were associated with greater postvaccine immunity and correlated with prior exposure to beta coronaviruses. These data support the ongoing policy to vaccinate PWH against SARS-CoV-2, and they underpin the need for long-term monitoring of responses after vaccination. AIDS/HIV COVID-19 Medicine R Matthew Pace verfasserin aut Mustapha Bittaye verfasserin aut Timothy Tipoe verfasserin aut Sandra Adele verfasserin aut Jasmini Alagaratnam verfasserin aut Parvinder K. Aley verfasserin aut M. Azim Ansari verfasserin aut Anna Bara verfasserin aut Samantha Broadhead verfasserin aut Anthony Brown verfasserin aut Helen Brown verfasserin aut Federica Cappuccini verfasserin aut Paola Cinardo verfasserin aut Wanwisa Dejnirattisai verfasserin aut Katie J. Ewer verfasserin aut Henry Fok verfasserin aut Pedro M. Folegatti verfasserin aut Jamie Fowler verfasserin aut Leila Godfrey verfasserin aut Anna L. Goodman verfasserin aut Bethany Jackson verfasserin aut Daniel Jenkin verfasserin aut Mathew Jones verfasserin aut Stephanie Longet verfasserin aut Rebecca A. Makinson verfasserin aut Natalie G. Marchevsky verfasserin aut Moncy Mathew verfasserin aut Andrea Mazzella verfasserin aut Yama F. Mujadidi verfasserin aut Lucia Parolini verfasserin aut Claire Petersen verfasserin aut Emma Plested verfasserin aut Katrina M. Pollock verfasserin aut Thurkka Rajeswaran verfasserin aut Maheshi N. Ramasamy verfasserin aut Sarah Rhead verfasserin aut Hannah Robinson verfasserin aut Nicola Robinson verfasserin aut Helen Sanders verfasserin aut Sonia Serrano verfasserin aut Tom Tipton verfasserin aut Anele Waters verfasserin aut Panagiota Zacharopoulou verfasserin aut Eleanor Barnes verfasserin aut Susanna Dunachie verfasserin aut Philip Goulder verfasserin aut Paul Klenerman verfasserin aut Gavin R. Screaton verfasserin aut Alan Winston verfasserin aut Adrian V.S. Hill verfasserin aut Sarah C. Gilbert verfasserin aut Miles Carroll verfasserin aut Andrew J. Pollard verfasserin aut Sarah Fidler verfasserin aut Julie Fox verfasserin aut Teresa Lambe verfasserin aut John Frater verfasserin aut In JCI Insight American Society for Clinical investigation, 2020 7(2022), 7 (DE-627)872610594 (DE-600)2874757-4 23793708 nnns volume:7 year:2022 number:7 https://doaj.org/article/446dfee8ec4944f5951afc9fd4bc0066 kostenfrei https://doi.org/10.1172/jci.insight.157031 kostenfrei https://doaj.org/toc/2379-3708 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 7 2022 7
spelling	(DE-627)DOAJ043577830 (DE-599)DOAJ446dfee8ec4944f5951afc9fd4bc0066 DE-627 ger DE-627 rakwb eng Ane Ogbe verfasserin aut Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Duration of protection from SARS-CoV-2 infection in people living with HIV (PWH) following vaccination is unclear. In a substudy of the phase II/III the COV002 trial (NCT04400838), 54 HIV+ male participants on antiretroviral therapy (undetectable viral loads, CD4+ T cells > 350 cells/μL) received 2 doses of ChAdOx1 nCoV-19 (AZD1222) 4–6 weeks apart and were followed for 6 months. Responses to vaccination were determined by serology (IgG ELISA and Meso Scale Discovery [MSD]), neutralization, ACE-2 inhibition, IFN-γ ELISpot, activation-induced marker (AIM) assay and T cell proliferation. We show that, 6 months after vaccination, the majority of measurable immune responses were greater than prevaccination baseline but with evidence of a decline in both humoral and cell-mediated immunity. There was, however, no significant difference compared with a cohort of HIV-uninfected individuals vaccinated with the same regimen. Responses to the variants of concern were detectable, although they were lower than WT. Preexisting cross-reactive T cell responses to SARS-CoV-2 spike were associated with greater postvaccine immunity and correlated with prior exposure to beta coronaviruses. These data support the ongoing policy to vaccinate PWH against SARS-CoV-2, and they underpin the need for long-term monitoring of responses after vaccination. AIDS/HIV COVID-19 Medicine R Matthew Pace verfasserin aut Mustapha Bittaye verfasserin aut Timothy Tipoe verfasserin aut Sandra Adele verfasserin aut Jasmini Alagaratnam verfasserin aut Parvinder K. Aley verfasserin aut M. Azim Ansari verfasserin aut Anna Bara verfasserin aut Samantha Broadhead verfasserin aut Anthony Brown verfasserin aut Helen Brown verfasserin aut Federica Cappuccini verfasserin aut Paola Cinardo verfasserin aut Wanwisa Dejnirattisai verfasserin aut Katie J. Ewer verfasserin aut Henry Fok verfasserin aut Pedro M. Folegatti verfasserin aut Jamie Fowler verfasserin aut Leila Godfrey verfasserin aut Anna L. Goodman verfasserin aut Bethany Jackson verfasserin aut Daniel Jenkin verfasserin aut Mathew Jones verfasserin aut Stephanie Longet verfasserin aut Rebecca A. Makinson verfasserin aut Natalie G. Marchevsky verfasserin aut Moncy Mathew verfasserin aut Andrea Mazzella verfasserin aut Yama F. Mujadidi verfasserin aut Lucia Parolini verfasserin aut Claire Petersen verfasserin aut Emma Plested verfasserin aut Katrina M. Pollock verfasserin aut Thurkka Rajeswaran verfasserin aut Maheshi N. Ramasamy verfasserin aut Sarah Rhead verfasserin aut Hannah Robinson verfasserin aut Nicola Robinson verfasserin aut Helen Sanders verfasserin aut Sonia Serrano verfasserin aut Tom Tipton verfasserin aut Anele Waters verfasserin aut Panagiota Zacharopoulou verfasserin aut Eleanor Barnes verfasserin aut Susanna Dunachie verfasserin aut Philip Goulder verfasserin aut Paul Klenerman verfasserin aut Gavin R. Screaton verfasserin aut Alan Winston verfasserin aut Adrian V.S. Hill verfasserin aut Sarah C. Gilbert verfasserin aut Miles Carroll verfasserin aut Andrew J. Pollard verfasserin aut Sarah Fidler verfasserin aut Julie Fox verfasserin aut Teresa Lambe verfasserin aut John Frater verfasserin aut In JCI Insight American Society for Clinical investigation, 2020 7(2022), 7 (DE-627)872610594 (DE-600)2874757-4 23793708 nnns volume:7 year:2022 number:7 https://doaj.org/article/446dfee8ec4944f5951afc9fd4bc0066 kostenfrei https://doi.org/10.1172/jci.insight.157031 kostenfrei https://doaj.org/toc/2379-3708 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 7 2022 7
allfields_unstemmed	(DE-627)DOAJ043577830 (DE-599)DOAJ446dfee8ec4944f5951afc9fd4bc0066 DE-627 ger DE-627 rakwb eng Ane Ogbe verfasserin aut Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Duration of protection from SARS-CoV-2 infection in people living with HIV (PWH) following vaccination is unclear. In a substudy of the phase II/III the COV002 trial (NCT04400838), 54 HIV+ male participants on antiretroviral therapy (undetectable viral loads, CD4+ T cells > 350 cells/μL) received 2 doses of ChAdOx1 nCoV-19 (AZD1222) 4–6 weeks apart and were followed for 6 months. Responses to vaccination were determined by serology (IgG ELISA and Meso Scale Discovery [MSD]), neutralization, ACE-2 inhibition, IFN-γ ELISpot, activation-induced marker (AIM) assay and T cell proliferation. We show that, 6 months after vaccination, the majority of measurable immune responses were greater than prevaccination baseline but with evidence of a decline in both humoral and cell-mediated immunity. There was, however, no significant difference compared with a cohort of HIV-uninfected individuals vaccinated with the same regimen. Responses to the variants of concern were detectable, although they were lower than WT. Preexisting cross-reactive T cell responses to SARS-CoV-2 spike were associated with greater postvaccine immunity and correlated with prior exposure to beta coronaviruses. These data support the ongoing policy to vaccinate PWH against SARS-CoV-2, and they underpin the need for long-term monitoring of responses after vaccination. AIDS/HIV COVID-19 Medicine R Matthew Pace verfasserin aut Mustapha Bittaye verfasserin aut Timothy Tipoe verfasserin aut Sandra Adele verfasserin aut Jasmini Alagaratnam verfasserin aut Parvinder K. Aley verfasserin aut M. Azim Ansari verfasserin aut Anna Bara verfasserin aut Samantha Broadhead verfasserin aut Anthony Brown verfasserin aut Helen Brown verfasserin aut Federica Cappuccini verfasserin aut Paola Cinardo verfasserin aut Wanwisa Dejnirattisai verfasserin aut Katie J. Ewer verfasserin aut Henry Fok verfasserin aut Pedro M. Folegatti verfasserin aut Jamie Fowler verfasserin aut Leila Godfrey verfasserin aut Anna L. Goodman verfasserin aut Bethany Jackson verfasserin aut Daniel Jenkin verfasserin aut Mathew Jones verfasserin aut Stephanie Longet verfasserin aut Rebecca A. Makinson verfasserin aut Natalie G. Marchevsky verfasserin aut Moncy Mathew verfasserin aut Andrea Mazzella verfasserin aut Yama F. Mujadidi verfasserin aut Lucia Parolini verfasserin aut Claire Petersen verfasserin aut Emma Plested verfasserin aut Katrina M. Pollock verfasserin aut Thurkka Rajeswaran verfasserin aut Maheshi N. Ramasamy verfasserin aut Sarah Rhead verfasserin aut Hannah Robinson verfasserin aut Nicola Robinson verfasserin aut Helen Sanders verfasserin aut Sonia Serrano verfasserin aut Tom Tipton verfasserin aut Anele Waters verfasserin aut Panagiota Zacharopoulou verfasserin aut Eleanor Barnes verfasserin aut Susanna Dunachie verfasserin aut Philip Goulder verfasserin aut Paul Klenerman verfasserin aut Gavin R. Screaton verfasserin aut Alan Winston verfasserin aut Adrian V.S. Hill verfasserin aut Sarah C. Gilbert verfasserin aut Miles Carroll verfasserin aut Andrew J. Pollard verfasserin aut Sarah Fidler verfasserin aut Julie Fox verfasserin aut Teresa Lambe verfasserin aut John Frater verfasserin aut In JCI Insight American Society for Clinical investigation, 2020 7(2022), 7 (DE-627)872610594 (DE-600)2874757-4 23793708 nnns volume:7 year:2022 number:7 https://doaj.org/article/446dfee8ec4944f5951afc9fd4bc0066 kostenfrei https://doi.org/10.1172/jci.insight.157031 kostenfrei https://doaj.org/toc/2379-3708 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 7 2022 7
allfieldsGer	(DE-627)DOAJ043577830 (DE-599)DOAJ446dfee8ec4944f5951afc9fd4bc0066 DE-627 ger DE-627 rakwb eng Ane Ogbe verfasserin aut Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Duration of protection from SARS-CoV-2 infection in people living with HIV (PWH) following vaccination is unclear. In a substudy of the phase II/III the COV002 trial (NCT04400838), 54 HIV+ male participants on antiretroviral therapy (undetectable viral loads, CD4+ T cells > 350 cells/μL) received 2 doses of ChAdOx1 nCoV-19 (AZD1222) 4–6 weeks apart and were followed for 6 months. Responses to vaccination were determined by serology (IgG ELISA and Meso Scale Discovery [MSD]), neutralization, ACE-2 inhibition, IFN-γ ELISpot, activation-induced marker (AIM) assay and T cell proliferation. We show that, 6 months after vaccination, the majority of measurable immune responses were greater than prevaccination baseline but with evidence of a decline in both humoral and cell-mediated immunity. There was, however, no significant difference compared with a cohort of HIV-uninfected individuals vaccinated with the same regimen. Responses to the variants of concern were detectable, although they were lower than WT. Preexisting cross-reactive T cell responses to SARS-CoV-2 spike were associated with greater postvaccine immunity and correlated with prior exposure to beta coronaviruses. These data support the ongoing policy to vaccinate PWH against SARS-CoV-2, and they underpin the need for long-term monitoring of responses after vaccination. AIDS/HIV COVID-19 Medicine R Matthew Pace verfasserin aut Mustapha Bittaye verfasserin aut Timothy Tipoe verfasserin aut Sandra Adele verfasserin aut Jasmini Alagaratnam verfasserin aut Parvinder K. Aley verfasserin aut M. Azim Ansari verfasserin aut Anna Bara verfasserin aut Samantha Broadhead verfasserin aut Anthony Brown verfasserin aut Helen Brown verfasserin aut Federica Cappuccini verfasserin aut Paola Cinardo verfasserin aut Wanwisa Dejnirattisai verfasserin aut Katie J. Ewer verfasserin aut Henry Fok verfasserin aut Pedro M. Folegatti verfasserin aut Jamie Fowler verfasserin aut Leila Godfrey verfasserin aut Anna L. Goodman verfasserin aut Bethany Jackson verfasserin aut Daniel Jenkin verfasserin aut Mathew Jones verfasserin aut Stephanie Longet verfasserin aut Rebecca A. Makinson verfasserin aut Natalie G. Marchevsky verfasserin aut Moncy Mathew verfasserin aut Andrea Mazzella verfasserin aut Yama F. Mujadidi verfasserin aut Lucia Parolini verfasserin aut Claire Petersen verfasserin aut Emma Plested verfasserin aut Katrina M. Pollock verfasserin aut Thurkka Rajeswaran verfasserin aut Maheshi N. Ramasamy verfasserin aut Sarah Rhead verfasserin aut Hannah Robinson verfasserin aut Nicola Robinson verfasserin aut Helen Sanders verfasserin aut Sonia Serrano verfasserin aut Tom Tipton verfasserin aut Anele Waters verfasserin aut Panagiota Zacharopoulou verfasserin aut Eleanor Barnes verfasserin aut Susanna Dunachie verfasserin aut Philip Goulder verfasserin aut Paul Klenerman verfasserin aut Gavin R. Screaton verfasserin aut Alan Winston verfasserin aut Adrian V.S. Hill verfasserin aut Sarah C. Gilbert verfasserin aut Miles Carroll verfasserin aut Andrew J. Pollard verfasserin aut Sarah Fidler verfasserin aut Julie Fox verfasserin aut Teresa Lambe verfasserin aut John Frater verfasserin aut In JCI Insight American Society for Clinical investigation, 2020 7(2022), 7 (DE-627)872610594 (DE-600)2874757-4 23793708 nnns volume:7 year:2022 number:7 https://doaj.org/article/446dfee8ec4944f5951afc9fd4bc0066 kostenfrei https://doi.org/10.1172/jci.insight.157031 kostenfrei https://doaj.org/toc/2379-3708 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 7 2022 7
allfieldsSound	(DE-627)DOAJ043577830 (DE-599)DOAJ446dfee8ec4944f5951afc9fd4bc0066 DE-627 ger DE-627 rakwb eng Ane Ogbe verfasserin aut Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Duration of protection from SARS-CoV-2 infection in people living with HIV (PWH) following vaccination is unclear. In a substudy of the phase II/III the COV002 trial (NCT04400838), 54 HIV+ male participants on antiretroviral therapy (undetectable viral loads, CD4+ T cells > 350 cells/μL) received 2 doses of ChAdOx1 nCoV-19 (AZD1222) 4–6 weeks apart and were followed for 6 months. Responses to vaccination were determined by serology (IgG ELISA and Meso Scale Discovery [MSD]), neutralization, ACE-2 inhibition, IFN-γ ELISpot, activation-induced marker (AIM) assay and T cell proliferation. We show that, 6 months after vaccination, the majority of measurable immune responses were greater than prevaccination baseline but with evidence of a decline in both humoral and cell-mediated immunity. There was, however, no significant difference compared with a cohort of HIV-uninfected individuals vaccinated with the same regimen. Responses to the variants of concern were detectable, although they were lower than WT. Preexisting cross-reactive T cell responses to SARS-CoV-2 spike were associated with greater postvaccine immunity and correlated with prior exposure to beta coronaviruses. These data support the ongoing policy to vaccinate PWH against SARS-CoV-2, and they underpin the need for long-term monitoring of responses after vaccination. AIDS/HIV COVID-19 Medicine R Matthew Pace verfasserin aut Mustapha Bittaye verfasserin aut Timothy Tipoe verfasserin aut Sandra Adele verfasserin aut Jasmini Alagaratnam verfasserin aut Parvinder K. Aley verfasserin aut M. Azim Ansari verfasserin aut Anna Bara verfasserin aut Samantha Broadhead verfasserin aut Anthony Brown verfasserin aut Helen Brown verfasserin aut Federica Cappuccini verfasserin aut Paola Cinardo verfasserin aut Wanwisa Dejnirattisai verfasserin aut Katie J. Ewer verfasserin aut Henry Fok verfasserin aut Pedro M. Folegatti verfasserin aut Jamie Fowler verfasserin aut Leila Godfrey verfasserin aut Anna L. Goodman verfasserin aut Bethany Jackson verfasserin aut Daniel Jenkin verfasserin aut Mathew Jones verfasserin aut Stephanie Longet verfasserin aut Rebecca A. Makinson verfasserin aut Natalie G. Marchevsky verfasserin aut Moncy Mathew verfasserin aut Andrea Mazzella verfasserin aut Yama F. Mujadidi verfasserin aut Lucia Parolini verfasserin aut Claire Petersen verfasserin aut Emma Plested verfasserin aut Katrina M. Pollock verfasserin aut Thurkka Rajeswaran verfasserin aut Maheshi N. Ramasamy verfasserin aut Sarah Rhead verfasserin aut Hannah Robinson verfasserin aut Nicola Robinson verfasserin aut Helen Sanders verfasserin aut Sonia Serrano verfasserin aut Tom Tipton verfasserin aut Anele Waters verfasserin aut Panagiota Zacharopoulou verfasserin aut Eleanor Barnes verfasserin aut Susanna Dunachie verfasserin aut Philip Goulder verfasserin aut Paul Klenerman verfasserin aut Gavin R. Screaton verfasserin aut Alan Winston verfasserin aut Adrian V.S. Hill verfasserin aut Sarah C. Gilbert verfasserin aut Miles Carroll verfasserin aut Andrew J. Pollard verfasserin aut Sarah Fidler verfasserin aut Julie Fox verfasserin aut Teresa Lambe verfasserin aut John Frater verfasserin aut In JCI Insight American Society for Clinical investigation, 2020 7(2022), 7 (DE-627)872610594 (DE-600)2874757-4 23793708 nnns volume:7 year:2022 number:7 https://doaj.org/article/446dfee8ec4944f5951afc9fd4bc0066 kostenfrei https://doi.org/10.1172/jci.insight.157031 kostenfrei https://doaj.org/toc/2379-3708 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 7 2022 7
language	English
source	In JCI Insight 7(2022), 7 volume:7 year:2022 number:7
sourceStr	In JCI Insight 7(2022), 7 volume:7 year:2022 number:7
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	AIDS/HIV COVID-19 Medicine R
isfreeaccess_bool	true
container_title	JCI Insight
authorswithroles_txt_mv	Ane Ogbe @@aut@@ Matthew Pace @@aut@@ Mustapha Bittaye @@aut@@ Timothy Tipoe @@aut@@ Sandra Adele @@aut@@ Jasmini Alagaratnam @@aut@@ Parvinder K. Aley @@aut@@ M. Azim Ansari @@aut@@ Anna Bara @@aut@@ Samantha Broadhead @@aut@@ Anthony Brown @@aut@@ Helen Brown @@aut@@ Federica Cappuccini @@aut@@ Paola Cinardo @@aut@@ Wanwisa Dejnirattisai @@aut@@ Katie J. Ewer @@aut@@ Henry Fok @@aut@@ Pedro M. Folegatti @@aut@@ Jamie Fowler @@aut@@ Leila Godfrey @@aut@@ Anna L. Goodman @@aut@@ Bethany Jackson @@aut@@ Daniel Jenkin @@aut@@ Mathew Jones @@aut@@ Stephanie Longet @@aut@@ Rebecca A. Makinson @@aut@@ Natalie G. Marchevsky @@aut@@ Moncy Mathew @@aut@@ Andrea Mazzella @@aut@@ Yama F. Mujadidi @@aut@@ Lucia Parolini @@aut@@ Claire Petersen @@aut@@ Emma Plested @@aut@@ Katrina M. Pollock @@aut@@ Thurkka Rajeswaran @@aut@@ Maheshi N. Ramasamy @@aut@@ Sarah Rhead @@aut@@ Hannah Robinson @@aut@@ Nicola Robinson @@aut@@ Helen Sanders @@aut@@ Sonia Serrano @@aut@@ Tom Tipton @@aut@@ Anele Waters @@aut@@ Panagiota Zacharopoulou @@aut@@ Eleanor Barnes @@aut@@ Susanna Dunachie @@aut@@ Philip Goulder @@aut@@ Paul Klenerman @@aut@@ Gavin R. Screaton @@aut@@ Alan Winston @@aut@@ Adrian V.S. Hill @@aut@@ Sarah C. Gilbert @@aut@@ Miles Carroll @@aut@@ Andrew J. Pollard @@aut@@ Sarah Fidler @@aut@@ Julie Fox @@aut@@ Teresa Lambe @@aut@@ John Frater @@aut@@
publishDateDaySort_date	2022-01-01T00:00:00Z
hierarchy_top_id	872610594
id	DOAJ043577830
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ043577830</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230308072853.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2022 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ043577830</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ446dfee8ec4944f5951afc9fd4bc0066</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Ane Ogbe</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Duration of protection from SARS-CoV-2 infection in people living with HIV (PWH) following vaccination is unclear. In a substudy of the phase II/III the COV002 trial (NCT04400838), 54 HIV+ male participants on antiretroviral therapy (undetectable viral loads, CD4+ T cells &gt; 350 cells/μL) received 2 doses of ChAdOx1 nCoV-19 (AZD1222) 4–6 weeks apart and were followed for 6 months. Responses to vaccination were determined by serology (IgG ELISA and Meso Scale Discovery [MSD]), neutralization, ACE-2 inhibition, IFN-γ ELISpot, activation-induced marker (AIM) assay and T cell proliferation. We show that, 6 months after vaccination, the majority of measurable immune responses were greater than prevaccination baseline but with evidence of a decline in both humoral and cell-mediated immunity. There was, however, no significant difference compared with a cohort of HIV-uninfected individuals vaccinated with the same regimen. Responses to the variants of concern were detectable, although they were lower than WT. Preexisting cross-reactive T cell responses to SARS-CoV-2 spike were associated with greater postvaccine immunity and correlated with prior exposure to beta coronaviruses. These data support the ongoing policy to vaccinate PWH against SARS-CoV-2, and they underpin the need for long-term monitoring of responses after vaccination.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">AIDS/HIV</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">COVID-19</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Matthew Pace</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Mustapha Bittaye</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Timothy Tipoe</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sandra Adele</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jasmini Alagaratnam</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Parvinder K. Aley</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">M. Azim Ansari</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Anna Bara</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Samantha Broadhead</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Anthony Brown</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Helen Brown</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Federica Cappuccini</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Paola Cinardo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Wanwisa Dejnirattisai</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Katie J. Ewer</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Henry Fok</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Pedro M. Folegatti</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jamie Fowler</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Leila Godfrey</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Anna L. Goodman</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Bethany Jackson</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Daniel Jenkin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Mathew Jones</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Stephanie Longet</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Rebecca A. Makinson</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Natalie G. Marchevsky</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Moncy Mathew</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Andrea Mazzella</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yama F. Mujadidi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Lucia Parolini</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Claire Petersen</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Emma Plested</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Katrina M. Pollock</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Thurkka Rajeswaran</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Maheshi N. Ramasamy</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sarah Rhead</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hannah Robinson</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Nicola Robinson</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Helen Sanders</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sonia Serrano</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Tom Tipton</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Anele Waters</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Panagiota Zacharopoulou</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Eleanor Barnes</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Susanna Dunachie</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Philip Goulder</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Paul Klenerman</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Gavin R. Screaton</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Alan Winston</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Adrian V.S. Hill</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sarah C. Gilbert</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Miles Carroll</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Andrew J. Pollard</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sarah Fidler</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Julie Fox</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Teresa Lambe</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">John Frater</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">JCI Insight</subfield><subfield code="d">American Society for Clinical investigation, 2020</subfield><subfield code="g">7(2022), 7</subfield><subfield code="w">(DE-627)872610594</subfield><subfield code="w">(DE-600)2874757-4</subfield><subfield code="x">23793708</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:7</subfield><subfield code="g">year:2022</subfield><subfield code="g">number:7</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/446dfee8ec4944f5951afc9fd4bc0066</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1172/jci.insight.157031</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2379-3708</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">7</subfield><subfield code="j">2022</subfield><subfield code="e">7</subfield></datafield></record></collection>
author	Ane Ogbe
spellingShingle	Ane Ogbe misc AIDS/HIV misc COVID-19 misc Medicine misc R Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV
authorStr	Ane Ogbe
ppnlink_with_tag_str_mv	@@773@@(DE-627)872610594
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut
collection	DOAJ
remote_str	true
illustrated	Not Illustrated
issn	23793708
topic_title	Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV AIDS/HIV COVID-19
topic	misc AIDS/HIV misc COVID-19 misc Medicine misc R
topic_unstemmed	misc AIDS/HIV misc COVID-19 misc Medicine misc R
topic_browse	misc AIDS/HIV misc COVID-19 misc Medicine misc R
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	JCI Insight
hierarchy_parent_id	872610594
hierarchy_top_title	JCI Insight
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)872610594 (DE-600)2874757-4
title	Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV
ctrlnum	(DE-627)DOAJ043577830 (DE-599)DOAJ446dfee8ec4944f5951afc9fd4bc0066
title_full	Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV
author_sort	Ane Ogbe
journal	JCI Insight
journalStr	JCI Insight
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2022
contenttype_str_mv	txt
author_browse	Ane Ogbe Matthew Pace Mustapha Bittaye Timothy Tipoe Sandra Adele Jasmini Alagaratnam Parvinder K. Aley M. Azim Ansari Anna Bara Samantha Broadhead Anthony Brown Helen Brown Federica Cappuccini Paola Cinardo Wanwisa Dejnirattisai Katie J. Ewer Henry Fok Pedro M. Folegatti Jamie Fowler Leila Godfrey Anna L. Goodman Bethany Jackson Daniel Jenkin Mathew Jones Stephanie Longet Rebecca A. Makinson Natalie G. Marchevsky Moncy Mathew Andrea Mazzella Yama F. Mujadidi Lucia Parolini Claire Petersen Emma Plested Katrina M. Pollock Thurkka Rajeswaran Maheshi N. Ramasamy Sarah Rhead Hannah Robinson Nicola Robinson Helen Sanders Sonia Serrano Tom Tipton Anele Waters Panagiota Zacharopoulou Eleanor Barnes Susanna Dunachie Philip Goulder Paul Klenerman Gavin R. Screaton Alan Winston Adrian V.S. Hill Sarah C. Gilbert Miles Carroll Andrew J. Pollard Sarah Fidler Julie Fox Teresa Lambe John Frater
container_volume	7
format_se	Elektronische Aufsätze
author-letter	Ane Ogbe
author2-role	verfasserin
title_sort	durability of chadox1 ncov-19 vaccination in people living with hiv
title_auth	Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV
abstract	Duration of protection from SARS-CoV-2 infection in people living with HIV (PWH) following vaccination is unclear. In a substudy of the phase II/III the COV002 trial (NCT04400838), 54 HIV+ male participants on antiretroviral therapy (undetectable viral loads, CD4+ T cells > 350 cells/μL) received 2 doses of ChAdOx1 nCoV-19 (AZD1222) 4–6 weeks apart and were followed for 6 months. Responses to vaccination were determined by serology (IgG ELISA and Meso Scale Discovery [MSD]), neutralization, ACE-2 inhibition, IFN-γ ELISpot, activation-induced marker (AIM) assay and T cell proliferation. We show that, 6 months after vaccination, the majority of measurable immune responses were greater than prevaccination baseline but with evidence of a decline in both humoral and cell-mediated immunity. There was, however, no significant difference compared with a cohort of HIV-uninfected individuals vaccinated with the same regimen. Responses to the variants of concern were detectable, although they were lower than WT. Preexisting cross-reactive T cell responses to SARS-CoV-2 spike were associated with greater postvaccine immunity and correlated with prior exposure to beta coronaviruses. These data support the ongoing policy to vaccinate PWH against SARS-CoV-2, and they underpin the need for long-term monitoring of responses after vaccination.
abstractGer	Duration of protection from SARS-CoV-2 infection in people living with HIV (PWH) following vaccination is unclear. In a substudy of the phase II/III the COV002 trial (NCT04400838), 54 HIV+ male participants on antiretroviral therapy (undetectable viral loads, CD4+ T cells > 350 cells/μL) received 2 doses of ChAdOx1 nCoV-19 (AZD1222) 4–6 weeks apart and were followed for 6 months. Responses to vaccination were determined by serology (IgG ELISA and Meso Scale Discovery [MSD]), neutralization, ACE-2 inhibition, IFN-γ ELISpot, activation-induced marker (AIM) assay and T cell proliferation. We show that, 6 months after vaccination, the majority of measurable immune responses were greater than prevaccination baseline but with evidence of a decline in both humoral and cell-mediated immunity. There was, however, no significant difference compared with a cohort of HIV-uninfected individuals vaccinated with the same regimen. Responses to the variants of concern were detectable, although they were lower than WT. Preexisting cross-reactive T cell responses to SARS-CoV-2 spike were associated with greater postvaccine immunity and correlated with prior exposure to beta coronaviruses. These data support the ongoing policy to vaccinate PWH against SARS-CoV-2, and they underpin the need for long-term monitoring of responses after vaccination.
abstract_unstemmed	Duration of protection from SARS-CoV-2 infection in people living with HIV (PWH) following vaccination is unclear. In a substudy of the phase II/III the COV002 trial (NCT04400838), 54 HIV+ male participants on antiretroviral therapy (undetectable viral loads, CD4+ T cells > 350 cells/μL) received 2 doses of ChAdOx1 nCoV-19 (AZD1222) 4–6 weeks apart and were followed for 6 months. Responses to vaccination were determined by serology (IgG ELISA and Meso Scale Discovery [MSD]), neutralization, ACE-2 inhibition, IFN-γ ELISpot, activation-induced marker (AIM) assay and T cell proliferation. We show that, 6 months after vaccination, the majority of measurable immune responses were greater than prevaccination baseline but with evidence of a decline in both humoral and cell-mediated immunity. There was, however, no significant difference compared with a cohort of HIV-uninfected individuals vaccinated with the same regimen. Responses to the variants of concern were detectable, although they were lower than WT. Preexisting cross-reactive T cell responses to SARS-CoV-2 spike were associated with greater postvaccine immunity and correlated with prior exposure to beta coronaviruses. These data support the ongoing policy to vaccinate PWH against SARS-CoV-2, and they underpin the need for long-term monitoring of responses after vaccination.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	7
title_short	Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV
url	https://doaj.org/article/446dfee8ec4944f5951afc9fd4bc0066 https://doi.org/10.1172/jci.insight.157031 https://doaj.org/toc/2379-3708
remote_bool	true
author2	Matthew Pace Mustapha Bittaye Timothy Tipoe Sandra Adele Jasmini Alagaratnam Parvinder K. Aley M. Azim Ansari Anna Bara Samantha Broadhead Anthony Brown Helen Brown Federica Cappuccini Paola Cinardo Wanwisa Dejnirattisai Katie J. Ewer Henry Fok Pedro M. Folegatti Jamie Fowler Leila Godfrey Anna L. Goodman Bethany Jackson Daniel Jenkin Mathew Jones Stephanie Longet Rebecca A. Makinson Natalie G. Marchevsky Moncy Mathew Andrea Mazzella Yama F. Mujadidi Lucia Parolini Claire Petersen Emma Plested Katrina M. Pollock Thurkka Rajeswaran Maheshi N. Ramasamy Sarah Rhead Hannah Robinson Nicola Robinson Helen Sanders Sonia Serrano Tom Tipton Anele Waters Panagiota Zacharopoulou Eleanor Barnes Susanna Dunachie Philip Goulder Paul Klenerman Gavin R. Screaton Alan Winston Adrian V.S. Hill Sarah C. Gilbert Miles Carroll Andrew J. Pollard Sarah Fidler Julie Fox Teresa Lambe John Frater
author2Str	Matthew Pace Mustapha Bittaye Timothy Tipoe Sandra Adele Jasmini Alagaratnam Parvinder K. Aley M. Azim Ansari Anna Bara Samantha Broadhead Anthony Brown Helen Brown Federica Cappuccini Paola Cinardo Wanwisa Dejnirattisai Katie J. Ewer Henry Fok Pedro M. Folegatti Jamie Fowler Leila Godfrey Anna L. Goodman Bethany Jackson Daniel Jenkin Mathew Jones Stephanie Longet Rebecca A. Makinson Natalie G. Marchevsky Moncy Mathew Andrea Mazzella Yama F. Mujadidi Lucia Parolini Claire Petersen Emma Plested Katrina M. Pollock Thurkka Rajeswaran Maheshi N. Ramasamy Sarah Rhead Hannah Robinson Nicola Robinson Helen Sanders Sonia Serrano Tom Tipton Anele Waters Panagiota Zacharopoulou Eleanor Barnes Susanna Dunachie Philip Goulder Paul Klenerman Gavin R. Screaton Alan Winston Adrian V.S. Hill Sarah C. Gilbert Miles Carroll Andrew J. Pollard Sarah Fidler Julie Fox Teresa Lambe John Frater
ppnlink	872610594
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
up_date	2024-07-03T18:19:10.194Z
_version_	1803582963916472320
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ043577830</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230308072853.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2022 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ043577830</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ446dfee8ec4944f5951afc9fd4bc0066</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Ane Ogbe</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Duration of protection from SARS-CoV-2 infection in people living with HIV (PWH) following vaccination is unclear. In a substudy of the phase II/III the COV002 trial (NCT04400838), 54 HIV+ male participants on antiretroviral therapy (undetectable viral loads, CD4+ T cells &gt; 350 cells/μL) received 2 doses of ChAdOx1 nCoV-19 (AZD1222) 4–6 weeks apart and were followed for 6 months. Responses to vaccination were determined by serology (IgG ELISA and Meso Scale Discovery [MSD]), neutralization, ACE-2 inhibition, IFN-γ ELISpot, activation-induced marker (AIM) assay and T cell proliferation. We show that, 6 months after vaccination, the majority of measurable immune responses were greater than prevaccination baseline but with evidence of a decline in both humoral and cell-mediated immunity. There was, however, no significant difference compared with a cohort of HIV-uninfected individuals vaccinated with the same regimen. Responses to the variants of concern were detectable, although they were lower than WT. Preexisting cross-reactive T cell responses to SARS-CoV-2 spike were associated with greater postvaccine immunity and correlated with prior exposure to beta coronaviruses. These data support the ongoing policy to vaccinate PWH against SARS-CoV-2, and they underpin the need for long-term monitoring of responses after vaccination.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">AIDS/HIV</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">COVID-19</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Matthew Pace</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Mustapha Bittaye</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Timothy Tipoe</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sandra Adele</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jasmini Alagaratnam</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Parvinder K. Aley</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">M. Azim Ansari</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Anna Bara</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Samantha Broadhead</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Anthony Brown</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Helen Brown</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Federica Cappuccini</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Paola Cinardo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Wanwisa Dejnirattisai</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Katie J. Ewer</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Henry Fok</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Pedro M. Folegatti</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jamie Fowler</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Leila Godfrey</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Anna L. Goodman</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Bethany Jackson</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Daniel Jenkin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Mathew Jones</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Stephanie Longet</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Rebecca A. Makinson</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Natalie G. Marchevsky</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Moncy Mathew</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Andrea Mazzella</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yama F. Mujadidi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Lucia Parolini</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Claire Petersen</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Emma Plested</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Katrina M. Pollock</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Thurkka Rajeswaran</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Maheshi N. Ramasamy</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sarah Rhead</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hannah Robinson</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Nicola Robinson</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Helen Sanders</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sonia Serrano</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Tom Tipton</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Anele Waters</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Panagiota Zacharopoulou</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Eleanor Barnes</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Susanna Dunachie</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Philip Goulder</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Paul Klenerman</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Gavin R. Screaton</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Alan Winston</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Adrian V.S. Hill</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sarah C. Gilbert</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Miles Carroll</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Andrew J. Pollard</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sarah Fidler</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Julie Fox</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Teresa Lambe</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">John Frater</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">JCI Insight</subfield><subfield code="d">American Society for Clinical investigation, 2020</subfield><subfield code="g">7(2022), 7</subfield><subfield code="w">(DE-627)872610594</subfield><subfield code="w">(DE-600)2874757-4</subfield><subfield code="x">23793708</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:7</subfield><subfield code="g">year:2022</subfield><subfield code="g">number:7</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/446dfee8ec4944f5951afc9fd4bc0066</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1172/jci.insight.157031</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2379-3708</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">7</subfield><subfield code="j">2022</subfield><subfield code="e">7</subfield></datafield></record></collection>
score	7.4020653

Nicht das Richtige dabei?

Schreiben Sie uns!

Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?